Pharma Focus Asia

Chime Biologics Enters into Agreement with Kings Pharm

Tuesday, September 26, 2023

Chime Biologics has entered into a strategic partnership with Kings Pharm. This collaboration signifies a significant development in the field of biologics, particularly in the context of biosimilar projects.

Under the terms of this agreement, Chime Biologics will utilise its extensive expertise in biosimilar projects to offer a comprehensive range of services to Kings Pharm. These services will encompass cell line development, early-stage process development, global clinical and commercial manufacturing, as well as assistance with the registration process for their biologics products.

This anti-tumour biosimilar is the first collaboration project between Kings Pharm and Chime Biologics to accelerate the development and commercialisation of anti-tumour biosimilar. The exclusive cooperation with Chime Biologics enables to further expand collaboration in the future, all for the benefit of patients.

This collaboration marks the inception of comprehensive biosimilar solution, and support Kings Pharm in bringing its biosimilars to market and enhancing global patient access to biologics.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024